 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 April 2001 | Volume 134 Issue 7 | Pages 573-586
Methylation of DNA is a biochemical modification that can influence gene expression and is involved in inactivating one of the two X chromosomes in women. Evidence that has accumulated in the past 10 years suggests that cancer cells usurp this physiologic mechanism and use it to their benefit by inactivating tumor suppressor genes and related proteins. However, the primary structure of the affected proteins remains intact; reversal of abnormalities in DNA methylation may therefore restore the tumor-suppressive function of these genes and provide a novel approach to cancer therapy. Two demethylating drugs, 5-azacytidine and 5-aza-deoxycytidine, are currently being tested in clinical trials, and several others are in preclinical development. In this article, the biological rationale for targeting aberrant methylation in cancer therapy is reviewed and completed phase I and II trials of this approach, some of which show promise for treatment of hematologic malignancies, are summarized.
Author and Article Information
From the University of Texas M.D. Anderson Cancer Center, Houston, Texas; and University of Florence, Florence, Italy.
Acknowledgment: The authors thank Maria E. Perez for assistance in preparing the manuscript.
Grant Support: Work in Dr. Issa's laboratory is supported by grants from the National Institutes of Health, The Leukemia and Lymphoma Society of America, and the American Cancer Society.
Requests for Single Reprints: Hagop M. Kantarjian, MD, M.D. Anderson Cancer Center, Leukemia Department, Box 61, 1515 Holcombe Boulevard, Houston, TX 77030.
Current Author Addresses: Dr. Santini: Department of Hematology, University of Florence, Viale Morgagni 85, Florence, Italy.
Drs. Kantarjian and Issa: M.D. Anderson Cancer Center, Leukemia Department, Box 61, 1515 Holcombe Boulevard, Houston, TX 77030. REVIEW
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
This article has been cited by other articles:
|
|
 |
|
  K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas Ann. Onc., October 1, 2008; 19(10): 1774 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Torrisani, N. Hanoun, H. Laurell, F. Lopez, J.-J. Maoret, A. Souque, C. Susini, P. Cordelier, and L. Buscail Identification of an Upstream Promoter of the Human Somatostatin Receptor, hSSTR2, Which Is Controlled by Epigenetic Modifications Endocrinology, June 1, 2008; 149(6): 3137 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation Circ. Res., April 25, 2008; 102(8): 933 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Markus, M. T. Garin, J. Bies, N. Galili, A. Raza, M. J. Thirman, M. M. Le Beau, J. D. Rowley, P. P. Liu, and L. Wolff Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in Acute Myelogenous Leukemia with inv(16) Cancer Res., February 1, 2007; 67(3): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood, January 1, 2007; 109(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Williams, N. Chakravarti, M. S. Kies, S.-I. Maruya, J. N. Myers, J. C. Haviland, R. S. Weber, R. Lotan, and A. K. El-Naggar Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors Clin. Cancer Res., December 15, 2006; 12(24): 7353 - 7358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, and J. L. Dai Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6687 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ghoshal, X. Li, J. Datta, S. Bai, I. Pogribny, M. Pogribny, Y. Huang, D. Young, and S. T. Jacob A Folate- and Methyl-Deficient Diet Alters the Expression of DNA Methyltransferases and Methyl CpG Binding Proteins Involved in Epigenetic Gene Silencing in Livers of F344 Rats J. Nutr., June 1, 2006; 136(6): 1522 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Yang, K. D. Doshi, S.-W. Choi, J. B. Mason, R. K. Mannari, V. Gharybian, R. Luna, A. Rashid, L. Shen, M. R.H. Estecio, et al. DNA Methylation Changes after 5-Aza-2'-Deoxycytidine Therapy in Patients with Leukemia. Cancer Res., May 15, 2006; 66(10): 5495 - 5503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Lee, S. Yegnasubramanian, X. Lin, and W. G. Nelson Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1 J. Biol. Chem., December 9, 2005; 280(49): 40749 - 40756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Ortmann, A. Burchert, K. Holzle, A. Nitsche, B. Wittig, A. Neubauer, and M. Schmidt Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region Nucleic Acids Res., December 7, 2005; 33(21): 6895 - 6905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hsi, X. Xi, Y. Wu, and S. M. Lippman The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells Mol. Cancer Ther., November 1, 2005; 4(11): 1740 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lyko and R. Brown DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies J Natl Cancer Inst, October 19, 2005; 97(20): 1498 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cortes and H. Kantarjian New Targeted Approaches in Chronic Myeloid Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6316 - 6324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa, V. Gharibyan, J. Cortes, J. Jelinek, G. Morris, S. Verstovsek, M. Talpaz, G. Garcia-Manero, and H. M. Kantarjian Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate J. Clin. Oncol., June 10, 2005; 23(17): 3948 - 3956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schneider-Stock, M. Diab-Assef, A. Rohrbeck, C. Foltzer-Jourdainne, C. Boltze, R. Hartig, P. Schonfeld, A. Roessner, and H. Gali-Muhtasib 5-aza-Cytidine Is a Potent Inhibitor of DNA Methyltransferase 3a and Induces Apoptosis in HCT-116 Colon Cancer Cells via Gadd45- and p53-Dependent Mechanisms J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 525 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Das and R. Singal DNA Methylation and Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Davis and E. O. Uthus DNA Methylation, Cancer Susceptibility, and Nutrient Interactions Experimental Biology and Medicine, November 1, 2004; 229(10): 988 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qiu, B. Zhou, H. Zou, X. Liu, P. G. Chu, R. Lopez, J. Shih, C. Chung, and Y. Yen Hypermethylation of Growth Arrest DNA Damage-Inducible Gene 45 {beta} Promoter in Human Hepatocellular Carcinoma Am. J. Pathol., November 1, 2004; 165(5): 1689 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Alleman, R. L. Tabios, G. V. R. Chandramouli, O. N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rodgers, N. A. Sopko, W. M. Linehan, and J. R. Vasselli The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2'-deoxycytidine Clin. Cancer Res., October 15, 2004; 10(20): 7011 - 7021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Valinluck, H.-H. Tsai, D. K. Rogstad, A. Burdzy, A. Bird, and L. C. Sowers Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2) Nucleic Acids Res., August 9, 2004; 32(14): 4100 - 4108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Itzkowitz and X. Yio Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, F. Arduini, A. Ruzzo, I. Bearzi, B. Humar, H. More, R. Silva, P. Muretto, P. Guilford, E. Testa, et al. Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2784 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoshida, K. Nosaka, J.-i. Yasunaga, I. Nishikata, K. Morishita, and M. Matsuoka Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells Blood, April 1, 2004; 103(7): 2753 - 2760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, F. Arduini, A. Ruzzo, A. Mandolesi, I. Bearzi, R. Silva, P. Muretto, E. Testa, D. Mari, M. Magnani, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs Ann. Onc., March 1, 2004; 15(3): 489 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa, G. Garcia-Manero, F. J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C. S. Rosenfeld, J. Cortes, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies Blood, March 1, 2004; 103(5): 1635 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Yang, M. R. H. Estecio, K. Doshi, Y. Kondo, E. H. Tajara, and J.-P. J. Issa A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements Nucleic Acids Res., February 18, 2004; 32(3): e38 - e38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. List, J. Vardiman, J.-P. J. Issa, and T. M. DeWitte Myelodysplastic Syndromes Hematology, January 1, 2004; 2004(1): 297 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La Rosee, K. Johnson, A. S. Corbin, E. P. Stoffregen, E. M. Moseson, S. Willis, M. M. Mauro, J. V. Melo, M. W. Deininger, and B. J. Druker In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines Blood, January 1, 2004; 103(1): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, B. Humar, and P. Guilford The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice Ann. Onc., December 1, 2003; 14(12): 1705 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, H. Wong, S. Ramanan, D. Cheong, A. Leong, and S. C. Hooi The Proline-Rich Acidic Protein Is Epigenetically Regulated and Inhibits Growth of Cancer Cell Lines Cancer Res., October 15, 2003; 63(20): 6658 - 6665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grassi, P. Maccaroni, R. Meyer, H. Kaiser, E. D'Ambrosio, E. Pascale, M. Grassi, A. Kuhn, P. Di Nardo, R. Kandolf, et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87 Carcinogenesis, October 1, 2003; 24(10): 1625 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yang, C.-M. Chen, P. Yan, T. H-M. Huang, H. Shi, M. Burger, I. Nimmrich, S. Maier, K. Berlin, and C. W. Caldwell The Androgen Receptor Gene is Preferentially Hypermethylated in Follicular Non-Hodgkin's Lymphomas Clin. Cancer Res., September 15, 2003; 9(11): 4034 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
|
|
B. Segura-Pacheco, C. Trejo-Becerril, E. Perez-Cardenas, L. Taja-Chayeb, I. Mariscal, A. Chavez, C. Acuna, A. M. Salazar, M. Lizano, and A. Duenas-Gonzalez Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy Clin. Cancer Res., May 1, 2003; 9(5): 1596 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, V. Gandhi, P. Kozuch, S. Faderl, F. Giles, J. Cortes, S. O'Brien, N. Ibrahim, F. Khuri, M. Du, et al. Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers J. Clin. Oncol., March 15, 2003; 21(6): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lin and W. G. Nelson Methyl-CpG-binding Domain Protein-2 Mediates Transcriptional Repression Associated with Hypermethylated GSTP1 CpG Islands in MCF-7 Breast Cancer Cells Cancer Res., January 15, 2003; 63(2): 498 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. N. J. de Grey An Engineer's Approach to the Development of Real Anti-Aging Medicine Sci. Aging Knowl. Environ., January 8, 2003; 2003(1): vp1 - vp1. [Abstract] [Full Text]
|
|
|
|
|
|
J. Goffin and E. Eisenhauer DNA methyltransferase inhibitors--state of the art Ann. Onc., November 1, 2002; 13(11): 1699 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zochbauer-Muller, J. D. Minna, and A. F. Gazdar Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications Oncologist, October 1, 2002; 7(5): 451 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Burdzy, K. T. Noyes, V. Valinluck, and L. C. Sowers Synthesis of stable-isotope enriched 5-methylpyrimidines and their use as probes of base reactivity in DNA Nucleic Acids Res., September 15, 2002; 30(18): 4068 - 4074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Friso and S.-W. Choi Gene-Nutrient Interactions and DNA Methylation J. Nutr., August 1, 2002; 132(8): 2382S - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Issa Epigenetic Variation and Human Disease J. Nutr., August 1, 2002; 132(8): 2388S - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wei, C.-M. Chen, G. Strathdee, J. Harnsomburana, C.-R. Shyu, F. Rahmatpanah, H. Shi, S.-W. Ng, P. S. Yan, K. P. Nephew, et al. Methylation Microarray Analysis of Late-Stage Ovarian Carcinomas Distinguishes Progression-free Survival in Patients and Identifies Candidate Epigenetic Markers Clin. Cancer Res., July 1, 2002; 8(7): 2246 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shi, P. S. Yan, C.-M. Chen, F. Rahmatpanah, C. Lofton-Day, C. W. Caldwell, and T. H.-M. Huang Expressed CpG Island Sequence Tag Microarray for Dual Screening of DNA Hypermethylation and Gene Silencing in Cancer Cells Cancer Res., June 1, 2002; 62(11): 3214 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian Treatment of Myelodysplastic Syndrome: Questions Raised by the Azacitidine Experience J. Clin. Oncol., May 15, 2002; 20(10): 2415 - 2416. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Friso, S.-W. Choi, D. Girelli, J. B. Mason, G. G. Dolnikowski, P. J. Bagley, O. Olivieri, P. F. Jacques, I. H. Rosenberg, R. Corrocher, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status PNAS, April 16, 2002; 99(8): 5606 - 5611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Richardson, L. B. Augustin, B. T. Kren, and C. J. Steer Gene Repair and Transposon-Mediated Gene Therapy Stem Cells, March 1, 2002; 20(2): 105 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]
|
|
|
|
|
|
P. S. Yan, C.-M. Chen, H. Shi, F. Rahmatpanah, S. H. Wei, C. W. Caldwell, and T. H.-M. Huang Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays Cancer Res., December 1, 2001; 61(23): 8375 - 8380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lin, K. Asgari, M. J. Putzi, W. R. Gage, X. Yu, B. S. Cornblatt, A. Kumar, S. Piantadosi, T. L. DeWeese, A. M. De Marzo, et al. Reversal of GSTP1 CpG Island Hypermethylation and Reactivation of {pi}-Class Glutathione S-Transferase (GSTP1) Expression in Human Prostate Cancer Cells by Treatment with Procainamide Cancer Res., December 1, 2001; 61(24): 8611 - 8616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, J. Goyal, S. Dhar, G. Dimri, E. Evron, S. Sukumar, D. E. Wazer, and V. Band CpG Methylation as a Basis for Breast Tumor-specific Loss of NES1/Kallikrein 10 Expression Cancer Res., November 1, 2001; 61(21): 8014 - 8021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Friso, S.-W. Choi, D. Girelli, J. B. Mason, G. G. Dolnikowski, P. J. Bagley, O. Olivieri, P. F. Jacques, I. H. Rosenberg, R. Corrocher, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status PNAS, April 16, 2002; 99(8): 5606 - 5611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Galm, M. R. Rountree, K. E. Bachman, K.-W. Jair, S. B. Baylin, and J. G. Herman Enzymatic Regional Methylation Assay: A Novel Method to Quantify Regional CpG Methylation Density Genome Res., January 1, 2002; 12(1): 153 - 157. [Abstract] [Full Text] [PDF]
|
|
Article
